替莫唑胺联合调强放疗治疗胶质母细胞瘤术后残留临床研究  

Temozolomide combined with intensity modulated radiation therapy(IMRT) for post-operative local residual of glioblastoma: a clinical study

作　　者：赵莺[1] 丁文秀[1] 尹小祥[1] 叶宏勋[1] 

机构地区：[1]泰兴市人民医院肿瘤放疗科,江苏泰兴225400

出　　处：《中华神经外科疾病研究杂志》2015年第4期334-337,共4页Chinese Journal of Neurosurgical Disease Research

摘　　要：目的分析比较替莫唑胺化疗联合调强放疗和单纯调强放疗治疗脑胶质母细胞瘤术后残留患者的疗效和安全性。方法胶质母细胞瘤术后局部有残留患者共36例,随机分为观察组和对照组,各18例。观察组在调强放疗时同步口服替莫唑胺化疗,对照组行单纯调强放疗,两组放疗方法相同。治疗期间观察治疗副作用,在所有患者治疗结束后定期随访,影像学动态观察患者肿瘤体积的变化及Karnofsky评分评价神经功能状态。结果观察组肿瘤体积的缩小和神经功能评分的改善均优于对照组(P<0.05)。两组生存率比较有统计学意义(P<0.05)。两组不良反应有恶心、呕吐、头痛及骨髓抑制等,程度均较轻,无重要脏器损害,未影响治疗。结论替莫唑胺化疗联合调强放疗疗效优于单纯调强放疗,且不良反应可耐受。Objective The efficacy and safety of Temozolomide plus intensity-modulated radiation therapy （IMRT） and IMRT alone in the treatment for post-operative local residual of glioblastoma.Methods A total of 36 patients with local residual of glioblastoma post-operatively were divided into observation group and control group randomly.In the observation group, intensity modulated radiation therapy （ IMRT ） was synchronized with temozolomide chemotherapy, while the control group with IMTR alone.Radiation method was the same in two groups. The side effects during tumor treatment were observed.All patients were followed up after treatment.The change of tumor size was observed and score of Karnofsky Performance status was used to evaluate the neurologic status.Results Both tumor volume reduction and the improvement of nerve function score in observation group were better than those of control group （P〈0.05）.There was significant difference in survival rate between two groups （P〈0.05）. Adverse reactions in two groups were slight, such as nausea, vomiting, headaches or bone marrow suppression, etc, and no important organ damage happened, which did no affect the treatment.Conclusion The curative effect of IMRT combined with temozolomide chemotherapy is better than IMRT alone, and the adverse reactions are tolerable.

关 键 词：胶质母细胞瘤 调强放疗 替莫唑胺 化疗 

分 类 号：R739[医药卫生—肿瘤]